TIMP3 and head and neck cancer: Rettori et al. collected saliva samples immediately after the last curative treatment and at a follow-up visit 6 months after treatment in which TIMP3 promoter hypermethylation was detected in the post-treatment salivary rinse as an independent prognostic marker for local recurrence-free survival in patients with head and neck cancer [16].